0
0
New findings from the IRONMAN study suggest that prostate-specific antigen (PSA) levels are a powerful tool for guiding treatment decisions in patients with metastatic hormone-sensitive prostate cancer. The results, presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting by Dr. Michael Ong of the Ottawa Hospital Research Institute, highlight how PSA measurements can help clinicians determine when to escalate or de-escalate therapy.
According to the study, a PSA level of 0.2 ng/mL or greater after 6–12 months of androgen deprivation therapy (ADT) or androgen receptor pathway inhibitor (ARPI) therapy predicts a poor prognosis and may indicate the need for treatment escalation. Conversely, an undetectable PSA nadir—defined as less than 0.2 ng/mL—suggests a good prognosis and could allow for consideration of treatment de-escalation.
Dr. Ong explained that while previous phase 3 trials had shown that PSA above 0.2 ng/mL is linked to poor prognosis, real-world data have been limited. The IRONMAN study provides robust evidence that absolute PSA at 6 and 12 months is prognostic in this patient population. Patients with a PSA under 0.1 ng/mL may be especially good candidates for de-escalation, while those with higher levels might benefit from clinical trials or intensified therapies.
These findings could help personalize care for men with metastatic prostate cancer, allowing clinicians to tailor treatment strategies based on individual PSA responses rather than a one-size-fits-all approach.
Disclaimer:
This article is based on information presented at a medical conference and published on Medscape. It is intended for informational purposes only and should not be considered medical advice. Always consult a qualified healthcare provider for diagnosis and treatment options tailored to your specific condition. The views expressed are those of the cited sources and do not necessarily reflect the opinions of any specific institution or organization.
